From Wikipedia, the free encyclopedia
Investigational analgesic drug
This article needs to be updated. Please help update this article to reflect recent events or newly available information. (October 2024)
Pharmaceutical compound
DSP-2230 Routes of(2S)-2-[[[3-cyclobutyl-5-(3,4,5-trifluorophenoxy)-3H-imidazo[4,5-b]pyridin-2-yl]methyl]amino]propanamide
FC1=CC(OC2=CC=C(N=C3CN([C@@H](C(N([H])[H])=O)C)[H])C(N3C4CCC4)=N2)=CC(F)=C1F
InChI=1S/C20H20F3N5O2/c1-10(19(24)29)25-9-16-26-15-5-6-17(27-20(15)28(16)11-3-2-4-11)30-12-7-13(21)18(23)14(22)8-12/h5-8,10-11,25H,2-4,9H2,1H3,(H2,24,29)/t10-/m1/s1
Key:HHXCJIMPEJSJTG-SNVBAGLBSA-N
DSP-2230 is a selective small-molecule Nav1.7 and Nav1.8 voltage-gated sodium channel blocker which is under development by Dainippon Sumitomo Pharma for the treatment of neuropathic pain.[1][2] As of June 2014, it is in phase I/phase II clinical trials.[1][2]
(
N02A,
N02B)
Opioids Opiates/opium SemisyntheticRetroSearch is an open source project built by @garambo | Open a GitHub Issue
Search and Browse the WWW like it's 1997 | Search results from DuckDuckGo
HTML:
3.2
| Encoding:
UTF-8
| Version:
0.7.4